StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) from a sell rating to a hold rating in a report published on Tuesday morning.
A number of other equities analysts have also recently weighed in on the stock. Roth Mkm lifted their price target on shares of Cyclacel Pharmaceuticals from $16.00 to $21.00 and gave the stock a buy rating in a research report on Tuesday, December 19th. Brookline Capital Management cut shares of Cyclacel Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, December 19th.
View Our Latest Report on Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Stock Up 5.6 %
Institutional Investors Weigh In On Cyclacel Pharmaceuticals
Several institutional investors and hedge funds have recently added to or reduced their stakes in CYCC. Renaissance Technologies LLC bought a new stake in Cyclacel Pharmaceuticals during the 2nd quarter worth about $68,000. Virtu Financial LLC acquired a new position in shares of Cyclacel Pharmaceuticals during the 2nd quarter worth about $33,000. Millennium Management LLC acquired a new position in shares of Cyclacel Pharmaceuticals during the 2nd quarter worth about $113,000. Two Sigma Investments LP acquired a new position in shares of Cyclacel Pharmaceuticals during the 3rd quarter worth about $98,000. Finally, HRT Financial LP acquired a new position in shares of Cyclacel Pharmaceuticals during the 4th quarter worth about $27,000. 23.58% of the stock is owned by institutional investors.
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Further Reading
- Five stocks we like better than Cyclacel Pharmaceuticals
- Stock Sentiment Analysis: How it Works
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Business Services Stocks Investing
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How Investors Can Find the Best Cheap Dividend Stocks
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.